Ambrx Biopharma (NYSE: AMAM)
FY 2021 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.480 | ||||||
REV | 7.455M |
H1 2021 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.630 | ||||||
REV | 5.132M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Ambrx Biopharma (NYSE: AMAM) through any online brokerage.
Other companies in Ambrx Biopharma’s space includes: CytomX Therapeutics (NASDAQ:CTMX), Adverum Biotechnologies (NASDAQ:ADVM), OncoCyte (NASDAQ:OCX), TCR2 Therapeutics (NASDAQ:TCRR) and Fusion Pharmaceuticals (NASDAQ:FUSN).
The latest price target for Ambrx Biopharma (NYSE: AMAM) was reported by Goldman Sachs on Tuesday, May 24, 2022. The analyst firm set a price target for 4.00 expecting AMAM to rise to within 12 months (a possible 40.35% upside). 6 analyst firms have reported ratings in the last year.
The stock price for Ambrx Biopharma (NYSE: AMAM) is $2.85 last updated June 24, 2022, 3:43 PM UTC.
There are no upcoming dividends for Ambrx Biopharma.
Ambrx Biopharma’s FY earnings are confirmed for Tuesday, April 26, 2022.
There is no upcoming split for Ambrx Biopharma.
Ambrx Biopharma is in the Health Care sector and Biotechnology industry. They are listed on the NYSE.